MedPath

Effect of drug for fetal lung maturation during pregnancy on mothers blood glucose levels and fetal well being

Phase 4
Conditions
Health Condition 1: O429- Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor
Registration Number
CTRI/2024/06/069376
Lead Sponsor
Government medical college and hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Pregnant women between 26-34 weeks of gestation with threatened preterm labor pains and premature rupture of membranes

2 Antenatal women between 34-39 weeks planned for lower segment cesarean section (LSCS)

Exclusion Criteria

1) Pregnant women with pre-existing diabetes and gestational diabetes mellitus.

2) Pregnant women with fetal growth restriction.

3) Patients who require immediate termination of pregnancy or are in established preterm labor.

4) Pregnant women with evidence of infection, where corticosteroid therapy may lead to flare-up of infection.

5) Patients with chronic kidney disease, and pre-existing adrenal and pancreatic dysfunction.

6) Pregnant women who have received tocolysis with beta-mimetic agents.

7) Multifetal gestation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath